Literature DB >> 16570858

HIV-1 coreceptors and their inhibitors.

N Ray1, R W Doms.   

Abstract

Entry of human immunodeficiency virus (HIV) into target cells is mediated by the viral Envelope glycoprotein (Env) and its coordinated interaction with a receptor (CD4) and a coreceptor (usually the chemokine receptors CCR5 or CXCR4). This review describes the identification of chemokine receptors as coreceptors for HIV-1 Env-mediated fusion, the determinants of chemokine receptor usage, and the impact of nonfunctional chemokine receptor alleles on HIV-1 resistance and disease progression. Due to the important role of chemokine receptors in HIV-1 entry, inhibitors of these coreceptors are good candidates for blocking entry and development of antiretroviral therapies. We discuss the different CCR5- and CXCR4-based antiretroviral drugs that have been developed thus far, highlighting the most promising drug candidates. Resistance to these coreceptor inhibitors as well as the impact of these drugs on clinical monitoring and treatment are also discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16570858     DOI: 10.1007/978-3-540-33397-5_5

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  53 in total

1.  Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Authors:  Binshan Shi; Christina Kitchen; Barbara Weiser; Douglas Mayers; Brian Foley; Kimdar Kemal; Kathryn Anastos; Marc Suchard; Monica Parker; Cheryl Brunner; Harold Burger
Journal:  Virology       Date:  2010-05-08       Impact factor: 3.616

2.  Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.

Authors:  Maciej Tarnowski; Katarzyna Grymula; Rui Liu; Joanna Tarnowska; Justyna Drukala; Janina Ratajczak; Robert A Mitchell; Mariusz Z Ratajczak; Magda Kucia
Journal:  Mol Cancer Res       Date:  2010-09-22       Impact factor: 5.852

Review 3.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

4.  Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.

Authors:  Neelanjana Ray; Jessamina E Harrison; Leslie A Blackburn; Jeffrey N Martin; Steven G Deeks; Robert W Doms
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 5.  Structure, function and physiological consequences of virally encoded chemokine seven transmembrane receptors.

Authors:  M M Rosenkilde; M J Smit; M Waldhoer
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

6.  Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction.

Authors:  Min Liang; Masakazu Kamata; Kevin N Chen; Nonia Pariente; Dong Sung An; Irvin S Y Chen
Journal:  J Gene Med       Date:  2010-03       Impact factor: 4.565

7.  Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers.

Authors:  Weizao Chen; Zhongyu Zhu; Yang Feng; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

Review 8.  Progress towards recombinant anti-infective antibodies.

Authors:  Jennifer C Pai; Jamie N Sutherland; Jennifer A Maynard
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2009-01

Review 9.  The role of stromal-derived factor-1--CXCR7 axis in development and cancer.

Authors:  Radoslaw B Maksym; Maciej Tarnowski; Katarzyna Grymula; Joanna Tarnowska; Marcin Wysoczynski; Riu Liu; Boguslaw Czerny; Janina Ratajczak; Magda Kucia; Mariusz Z Ratajczak
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

10.  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.

Authors:  Reem Berro; Rogier W Sanders; Min Lu; Per J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.